Lineage Cell Therapeutics (LCTX) announced that the first-ever chronic spinal cord injury patient has been treated in the company’s DOSED clinical study at UC San Diego Health. The DOSED study is designed to evaluate the safety and utility of a new parenchymal spinal delivery system, a novel delivery device developed to deliver OPC1 directly to the site of injury in patients with spinal cord injury, and will enroll both subacute and chronic SCI patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LCTX:
- Lineage Therap Holds Annual Meeting, Elects Directors
- Largest borrow rate increases among liquid names
- Buy Rating Affirmed for Lineage Cell Therapeutics: Promising OpRegen Data and Long-term Potential
- Lineage Therap Reports Promising OpRegen Study Results
- Lineage Cell Therapeutics announces RG6501 study meets primary endpoint at CTS